Zu den Inhalten springen
Marien Hospital Herne
St. Elisabeth Gruppe
HomeHome
Klinik für Urologie

MSD MK-3475-B15

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)

© Marien Hospital Herne | Impressum | . Datenschutz | . Datenschutz­einstellungen anpassen.